MedTrace Logo

A Study of TRS01 in Subjects With Active Non-infectious Anterior Uveitis Including Subjects With Uveitic Glaucoma

NCT05042609 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 142

Last updated 2026-05-20

Study results available
· View outcomes & findings →

Summary

The primary objective of this study is to evaluate the efficacy and safety of TRS01 eye drops compared to active comparator in subjects with active non-infectious anterior uveitis with or without uveitic glaucoma

Conditions

  • Non-infectious Anterior Uveitis
  • Uveitic Glaucoma

Interventions

DRUG

FDA approved steroid eye drop (masked)

FDA approved steroid eye drop Dosed four times a day (QID)

DRUG

TRS01

TRS01 eye drops Dosed four times a day (QID)

Sponsors & Collaborators

  • Tarsier Pharma

    lead INDUSTRY

Principal Investigators

  • Lexitas Clinical Trials · Lexitas

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
0 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-09-20
Primary Completion
2023-06-29
Completion
2023-06-29
FDA Drug
Yes

Countries

  • United States
  • France
  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05042609 on ClinicalTrials.gov